Targeting DHFR in parasitic protozoa.
Drug Discov Today
; 10(2): 121-8, 2005 Jan 15.
Article
en En
| MEDLINE
| ID: mdl-15718161
ABSTRACT
Parasitic apicomplexans are responsible for some of the most severe worldwide health problems, including malaria, toxoplasmosis and cryptosporidiosis. These parasites are characterized by a bifunctional enzyme, dihydrofolate reductase-thymidylate synthase (DHFR-TS), which has a crucial role in pyrimidine biosynthesis. Inhibitors of DHFR have been successful in the treatment of toxoplasmosis and malaria. However, there is currently no effective therapy for cryptosporidiosis, and despite early successes against malaria, resistance to DHFR inhibitors in malaria parasites has now become a global problem. Novel DHFR inhibitors, designed using the recently revealed crystal structures of the enzymes from two parasitic protozoa, are in development.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Infecciones por Protozoos
/
Tetrahidrofolato Deshidrogenasa
/
Eucariontes
/
Antagonistas del Ácido Fólico
/
Antiprotozoarios
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Drug Discov Today
Asunto de la revista:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Año:
2005
Tipo del documento:
Article
País de afiliación:
Estados Unidos